Welcome to LookChem.com Sign In|Join Free

CAS

  • or

96566-25-5

Post Buying Request

96566-25-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentoxy]-3,4-dihydro-2H-chromene-2-carboxylic acid

    Cas No: 96566-25-5

  • No Data

  • No Data

  • No Data

  • BOC Sciences
  • Contact Supplier

96566-25-5 Usage

Originator

Ulpax,Roche

Manufacturing Process

A solution of 109.8 g (0.75 mol) of diethyl oxalate and 65 g (0.427 mol) of 2',4'-dihydroxyacetophenone in 100 mL of EtOH was added slowly under Ar, with cooling, to a stirred solution of NaOEt (from 40 g of Na and 550 mL of EtOH). The mixture was stirred at 50°C for 3 h, cooled to room temperature, and poured into a separatory funnel containing 500 mL of 2 N HCl. It was extracted with CH2CH2 washed with 500 mL of saturated NaHCO3, dried and evaporated to give a red oil, which was dissolved in 250 mL of EtOH and 10 mL of conc. HCl. The mixture was boiled under reflux for 1 h, cooled to ca. 10°C and the product was collected by filtration. It was washed with some EtOH followed by hexane to give 86.0 g (86% yield) of ethyl 7-hydroxy-4-oxo- 4H-1-benzopyran-2-carboxylate: m.p. 218-223°C. Crystallization of a portion from hot AcOH gave an analytical sample: m.p. 221-223°C. A solution of 80 g (0.34 mol) of ethyl 7-hydroxy-4-oxo-4H-1-benzopyran-2- carboxylate in 60 mL of AcOH and 275 mL of THF was hydrogenated over 4.0 g of 10% Pd on charcoal at 45°C and 65 psi. After hydrogen absorption ceased, the catalyst was removed by filtration and the solvents were evaporated under reduced pressure. Crystallization from CCl4 gave 65 g (85%) of ethyl (R,S)-3,4-dihydro-7-hydroxy-2H-1-benzopyran-2-carboxylate: m.p. 80-82°C. A stirred mixture of 65 g (0.293 mol) of ethyl (R,S)-3,4-dihydro-7-hydroxy- 2H-1-benzopyran-2-carboxylate in 650 mL of AcOH, 1.5 mL of acetic anhydride, and 65 mL of BF3·OEt2 was heated at reflux for 18 h and evaporated. To the residue was added 700 mL of water, and the mixture was stirred at room temperature for 1.0 h. The product was collected by filtration and washed with hexane. It was then dissolved in 900 mL of MeOH, treated with 6.6 g of p-toluenesulfonic acid, boiled under reflux for 18 h, and cooled to 0°C. The product was collected by filtration to give 52 g (70% yield) of ethyl (R,S)-3,4-dihydro-7-hydroxy-2H-1-benzopyran-2-carboxylate: m.p. 140- 142°C. A 1 L, 3-necked, round-bottomed flask equipped with a mechanical stirrer and an Ar bubbler was charged with 37.5 g (0.179 moles) of 5-bromo-1-pentanyl acetate, 350 mL of anhyd. DMSO, 40.7 g (0.163 mol) of ethyl (R,S)-3,4- dihydro-7-hydroxy-2H-1-benzopyran-2-carboxylate, and 51.0 g (0.369 mol) of powdered potassium carbonate. The mixture was stirred at room temperature for 18 h, poured into 1.0 L of water and extracted into EtOAc (2*1 L). The extract was washed with 1 L of brine, dried and evaporated. The residue was dissolved in 200 mL of ether, cooled to 57°C and, with stirring, diluted with petroleum ether. The product was collected by filtration, washed with a little 1:1 ether-petroleum ether (b.p. 40-60°C) and dried to give 60.0 g (97%) of methyl (R,S)-6-acetyl-3,4-dihydro-7-((5-acetoxypentyl)oxy-2H-1-benzopyran- 2-carboxylate: m.p.51-53°C. A solution of 72.08 g (0.19 mol) of 5-bromo-1-pentanyl acetate in 1.4 L of MeOH was treated with 38 mL of a 1.0 molar solution of tetrabutylammonium hydroxide and the mixture was stirred at room temperature for 3.0 h, 3.0 mL of AcOH was added and the solution was evaporated at 35°C. The residue was dissolved in 400 mL of EtOAc and the solution was washed with saturated NaHCO3, brine, dried, and evaporated to give 60.45 g (94% yield) of the intermediate hydroxy ester (an analytical sample may be obtained by crystallization from 70% EtOAc in hexane, m.p. 58-61°C. A stirred solution of 60.25 g of the hydroxyester in 700 mL of EtOAc was cooled to 5°C and treated with 75.5 mL (3 equiv.) of triethylamine and 32.6 mL (2.35 equiv.) of methanesulfonyl chloride. The mixture was stirred at 6°C for 2.0 h, transferred to a separatory funnel and washed sequentially with water, 2 N HCl, and brine. Concentration of the EtOAc to ca. 300 mL and dilution cooled to 0°C and treated with 75.5 mL (3 equiv.) of triethylamine and 32.6 mL (2.35 equiv.) of methanesulfonyl chloride. The mixture was stirred at 6°C for 2.0 h transferred to a separatory funnel and washed sequentially with water, 2 N HCl, and brine. Concentration of the EtOAc to ca. 300 mL and dilution with 250 mL of hexane led to crystallization (0°C, 18 h). The product was collected by filtration and washed with some cold hexane - EtOAc (1:1) to give 66 g (84% yield) of methyl (R,S)-6-acetyl-3,4-dihydro-7-[5- [(methylsufonyl)oxy]pentyloxy]-2H-1-benzopyran-2-carboxylate: m.p. 73- 76°C. A mixture of 66.13 g (0.159 mol) of methyl (R,S)-6-acetyl-3,4-dihydro-7-[5- [(methylsufonyl)oxy]pentyloxy]-2H-1-benzopyran-2-carboxylate, 30.99 g (0.159 mol) of 1-[2,4-dihydroxy-3-propylphenyl)ethanone, 33.07 g (0.239 mol) of pulverized potassium carbonate, 5.16 g (15.9 mmol) of tris(3,6- dioxahepyl)amine in 900 mL of toluene was stirred under Ar at reflux for 6 h and then at room temperature overnight. The mixture was poured into 300 mL of water and the organic phase was separated, washed with brine, dried and evaporated to give 84.3 g of methyl (R,S)-6-acetyl-7-[5-(4-acetyl-3- hydroxy-2-propylphenoxy)pentoxy]-3,4-dihydro-2H-1-benzopyran-2- carboxilate. Crystallization from MeOH (0°C, 18 h) gave 66 g (81% yield), m.p. 77-80°C.A stirred solution of 55.82 g (0.109 mol) of methyl (R,S)-6-acetyl-7-[5-(4- acetyl-3-hydroxy-2-propylphenoxy)pentoxy]-3,4-dihydro-2H-1-benzopyran-2- carboxylate in 725 mL of MeOH was treated with 4.45 g (0.111 mol) of NaOH in 20 mL of water and the mixture was stirred at reflux for 1.25 h. It was cooled, concentrated to a volume of ca 360 mL, diluted with 310 mL of ether and left at 0°C overnight. The product was collected by filtration, dried in to give 45.76 g of (R,S)-6-acetyl-7-[[5-(4-acetyl-3-hydroxy-2- propylphenoxy)pentyl]oxy]-3,4-dihydro-2H-H-benzopyran-2-carboxylic acid sodium salt (Ablukast) as the monohydrate. A further 12.27 g of product was obtained from the mother liquor to give a total yield of 99%.

Check Digit Verification of cas no

The CAS Registry Mumber 96566-25-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,6,5,6 and 6 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 96566-25:
(7*9)+(6*6)+(5*5)+(4*6)+(3*6)+(2*2)+(1*5)=175
175 % 10 = 5
So 96566-25-5 is a valid CAS Registry Number.
InChI:InChI=1/C28H34O8/c1-4-8-21-23(12-10-20(17(2)29)27(21)31)34-13-6-5-7-14-35-26-16-25-19(15-22(26)18(3)30)9-11-24(36-25)28(32)33/h10,12,15-16,24,31H,4-9,11,13-14H2,1-3H3,(H,32,33)

96566-25-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentoxy]-3,4-dihydro-2H-chromene-2-carboxylic acid

1.2 Other means of identification

Product number -
Other names rac-6-acetyl-7-<<5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyl>oxy>-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:96566-25-5 SDS

96566-25-5Downstream Products

96566-25-5Relevant articles and documents

Method of diminishing the adverse effects of interleukin-2

-

, (2008/06/13)

A method and composition for preserving or enhancing the beneficial effects of interlude-2 (IL-2) while simultaneously mitigating the adverse effects of IL-2 on a subject is disclosed. The method involves administering an amount of a leukotriene B4 (LTB4) antagonist, preferably a LTB4 receptor antagonistic, to a subject exhibiting adverse pharmacological effects due to exogenous IL-2, where the amount administered to the subject is sufficient to decrease the IL-2 induces adverse effects. Also disclosed is an article of manufacturing comprising a composition of the leukotriene B4 antagonist in combination with labeling instructions for treatment. Also disclosed is a method for preparing a pharmaceutical composition. Generally the LTB4 antagonist will reduce the IL-2-induced adverse effects while preserving or enhancing the anti tumor, antiviral, or immunostimulatory effects of IL-2, thereby improving the therapeutic index of IL-2.

Synthesis of the leukotriene antagonist ablukast

Manchand,Micheli,Saposnik

, p. 9391 - 9398 (2007/10/02)

An efficient synthesis of the leukotriene antagonist ablukast (5) has been achieved starting from 2,4-dihydroxyacetophenone. The latter, on a Claisen condensation with ethyl oxalate, followed by hydrogenation, gave the chromane ester 7, which was subjected to a Fries rearrangement (AcOH/BF3·OEt2) and the product, after transesterification with methanol, was alkylated with 5-bromo-1-pentanyl acetate to afford the acetate 9. A novel methanolysis of 9 with methanol in the presence of tetra-n-butylammonium hydroxide followed by mesylation of the derived alcohol furnished the mesylate 10. Alkylation of the acetophenone derivative 16 with 10 using K2CO3 in the presence of tris(3,6-dioxaheptyl)amine and saponification gave 5.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 96566-25-5